series-a
Stage
1
Investors
About
Amberstone Biosciences develops tumor microenvironment activated immunotherapeutics using its proprietary T-MATE™ technology to precisely trigger immune responses in tumors while minimizing harm to healthy tissues.
Explore Amberstone Biosciences's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.